Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

NCT02138825 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

147

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.

Conditions

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Interventions

DRUG: Riociguat (Adempas, BAY63-2521)
DRUG: Placebo

Sponsor

Bayer